These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 12168109)

  • 21. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.
    Mulligan JM; Greene LM; Cloonan S; Mc Gee MM; Onnis V; Campiani G; Fattorusso C; Lawler M; Williams DC; Zisterer DM
    Mol Pharmacol; 2006 Jul; 70(1):60-70. PubMed ID: 16571652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microtubule-associated proteins as targets in cancer chemotherapy.
    Bhat KM; Setaluri V
    Clin Cancer Res; 2007 May; 13(10):2849-54. PubMed ID: 17504982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents?
    Fojo T
    J Natl Cancer Inst; 2006 Oct; 98(19):1345-7. PubMed ID: 17018774
    [No Abstract]   [Full Text] [Related]  

  • 24. Microtubule assembly dynamics: an attractive target for anticancer drugs.
    Singh P; Rathinasamy K; Mohan R; Panda D
    IUBMB Life; 2008 Jun; 60(6):368-75. PubMed ID: 18384115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
    J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities.
    Liaw TY; Chang MH; Kavallaris M
    Curr Drug Targets; 2007 Jun; 8(6):739-49. PubMed ID: 17584029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system.
    Sengupta S; Smitha SL; Thomas NE; Santhoshkumar TR; Devi SK; Sreejalekshmi KG; Rajasekharan KN
    Br J Pharmacol; 2005 Aug; 145(8):1076-83. PubMed ID: 15951833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance.
    Zhang X; Smith CD
    Mol Pharmacol; 1996 Feb; 49(2):288-94. PubMed ID: 8632761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
    Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
    Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies.
    Wilson L; Jordan MA
    J Chemother; 2004 Nov; 16 Suppl 4():83-5. PubMed ID: 15688618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
    Dumontet C; Sikic BI
    J Clin Oncol; 1999 Mar; 17(3):1061-70. PubMed ID: 10071301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics.
    Kanakkanthara A; Teesdale-Spittle PH; Miller JH
    Anticancer Agents Med Chem; 2013 Jan; 13(1):147-58. PubMed ID: 22583426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
    Aparicio LM; Pulido EG; Gallego GA
    Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug target interaction of tubulin-binding drugs in cancer therapy.
    Sengupta S; Thomas SA
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1433-47. PubMed ID: 17069528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.
    Tinley TL; Randall-Hlubek DA; Leal RM; Jackson EM; Cessac JW; Quada JC; Hemscheidt TK; Mooberry SL
    Cancer Res; 2003 Jun; 63(12):3211-20. PubMed ID: 12810650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microtubule-stabilizing activity of zampanolide, a potent macrolide isolated from the Tongan marine sponge Cacospongia mycofijiensis.
    Field JJ; Singh AJ; Kanakkanthara A; Halafihi T; Northcote PT; Miller JH
    J Med Chem; 2009 Nov; 52(22):7328-32. PubMed ID: 19877653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.
    Buey RM; Barasoain I; Jackson E; Meyer A; Giannakakou P; Paterson I; Mooberry S; Andreu JM; Díaz JF
    Chem Biol; 2005 Dec; 12(12):1269-79. PubMed ID: 16356844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.